Core Viewpoint - The collaboration between Insilico Medicine and a global independent pharmaceutical company, Sviat, is a significant multi-year R&D partnership valued at up to $888 million, focusing on challenging oncology targets and the development of new therapeutic drugs [1] Group 1: Partnership Details - The partnership will leverage Insilico's proprietary AI platform, Pharma.AI, to identify and develop potential drug candidates [1] - Insilico is eligible for an upfront payment of up to $32 million and milestone payments related to recent R&D achievements [1] - Sviat will co-fund the R&D costs and lead subsequent clinical validation and commercialization processes [1] Group 2: Statements from Executives - Christophe Thurieau, Executive Director at Sviat, emphasized the commitment to using cutting-edge technology to address unmet medical needs and benefit patients [1] - Alex Zhavoronkov, CEO of Insilico, expressed excitement about the collaboration, highlighting the recognition of the company's AI drug development capabilities and the potential for AI to enhance the drug development process [1]

格隆汇1月5日丨英矽智能(03696.HK)发布公告，集团已与一家由基金会管理的全球独立制药公司施维雅 达成多年期研发合作。该合作价值高达8.88亿美元，将充分利用集团自主研发的人工智能平台 Pharma.AI，聚焦于抗肿瘤领域具有挑战性的靶点，识别并开发全新的治疗药物。根据协议，集团将有 资格获得最高3,200万美元的首付款及近期研发里程碑付款，并将主导运用人工智能技术平台，发现及 开发符合既定标准的潜在候选药物，而施维雅将共同承担研发成本，主导后续临床验证及商业化进程。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 INSILICO MEDICINE InSilico Medicine Cayman TopCo 英矽智能 （於開曼群島註冊成立的有限公司） （股份代號：3696） 有關與施維雅達成多年期抗腫瘤藥物研發合作之自願公告 本公告乃由英矽智能（「本公司」，連同其附屬公司統稱「本集團」）自願作出。 英矽智能在人工智能驅動的腫瘤藥物研發方面擁有豐富經驗，公司已建立起覆 蓋多種癌症適應症、兼具中度新穎機制與成熟機制的腫瘤管線。其中，具潛力 成為同類最佳(best-in-class)療法的泛TEAD抑制劑ISM6331以及MAT2A抑制劑 ISM3412，均已啟動全球多中心I期臨床試驗。此外，公司還有四個腫瘤專案已全 部或部分對外授權予合作夥伴，相關I期臨床試驗正穩步推進中。 本公司謹此知會隨附新聞稿的本公司股東及潛在投資者，本集團已與一家由基金 會管理的全球獨立製藥公司施維雅達成多年期研發合作。該合作價值高達8.88 ...

Investment Rating - The report does not explicitly provide an investment rating for the industry or companies discussed. Core Insights - The technology industry experienced 196 financing events globally from December 22, 2025, to January 1, 2026, with 181 events in China and 15 abroad, highlighting significant investment activity in advanced manufacturing, artificial intelligence, and enterprise services [9]. - The semiconductor sector is witnessing advancements with the global release of high-purity P-type SiC substrates and the development of the first 12-inch high-quality silicon carbide epitaxial wafer, which are expected to enhance production efficiency and reduce costs in the semiconductor industry [33][38]. - The artificial intelligence sector is advancing with new technologies such as the TurboDiffusion framework for video generation, which can accelerate video creation by up to 200 times, and the introduction of the "Shan Hai" S30FP/S30P SPU IP, which provides comprehensive security solutions for high-performance computing chips [4][41]. Summary by Sections Financing Overview - A total of 196 financing events occurred in the technology sector during the specified period, with advanced manufacturing, artificial intelligence, and enterprise services leading the way in terms of the number of events [9]. IPO Updates - Several companies went public, including: - **InSilico Medicine** listed on the Hong Kong Stock Exchange, focusing on AI-driven drug discovery, significantly reducing the time for drug development from an average of 4.5 years to 12-18 months [11][12]. - **Tiansu Measurement** listed on the Shenzhen Stock Exchange, providing independent third-party measurement and testing services across various industries [15][16]. - **Nobikang** also listed on the Hong Kong Stock Exchange, specializing in AI solutions for railway and power companies [18][19]. Semiconductor Sector Developments - **SuperChip** launched a high-purity P-type SiC substrate, addressing critical impurities that have historically hindered the industry, thus enhancing the reliability of high-voltage IGBT devices [33][36]. - **Hantian Technology** developed the world's first 12-inch high-quality silicon carbide epitaxial wafer, which is expected to significantly improve production efficiency and lower costs in the semiconductor industry [38][40]. - **Arm Technology** introduced the "Shan Hai" S30FP/S30P SPU IP, enhancing security for high-performance computing applications [41][42]. AI and Quantum Technology Innovations - The report highlights advancements in AI, including a collaboration between Shenshu Technology and Tsinghua University to accelerate video generation, and IBM's new framework for large language model planning [4][41]. - In quantum technology, IonQ has established a significant presence in South Korea with its quantum computing capabilities, marking a strategic expansion in the global infrastructure [4][6].

Core Insights - The collaboration between Insilico Medicine and Haizheng Pharmaceutical has achieved a significant milestone by nominating a preclinical candidate compound (PCC) within approximately 8 months of their strategic partnership [1][2][3] Group 1: Collaboration Details - The partnership began in April 2025, focusing on innovative drug development through the integration of AI technology and traditional drug discovery methods [1] - Insilico Medicine is responsible for early-stage research, including target identification, lead compound discovery, and preclinical studies, while Haizheng Pharmaceutical will handle the clinical trial application and subsequent clinical trial processes [1][2] Group 2: Project Progress and Impact - Within the 8-month collaboration, Insilico Medicine efficiently advanced the early research and completed the necessary preclinical studies, meeting the PCC nomination standards set by both companies [2] - The project highlights the potential of AI-driven innovation in drug development, particularly in addressing unmet clinical needs in novel target areas [2][3] Group 3: Strategic Implications - The successful nomination of the PCC within a short timeframe validates the delivery capabilities of Insilico Medicine and the collaborative efficiency of both companies [3] - This collaboration serves as a representative case for local enterprises exploring new pathways in drug development through the synergy of AI platforms and pharmaceutical industrialization capabilities [3]

Group 1 - The collaboration between Insilico Medicine and Haizheng Pharmaceutical has achieved a milestone by nominating a preclinical candidate compound (PCC) within approximately 8 months of their strategic partnership [1][2] - The partnership began in April 2025, focusing on deep collaboration in drug discovery and development by integrating AI technology with traditional drug development advantages [1] - Insilico Medicine is responsible for early-stage research, including target identification, lead compound discovery, and preclinical studies, while Haizheng Pharmaceutical will handle clinical trial application support and subsequent clinical trial implementation [1] Group 2 - Insilico Medicine's Pharma.AI platform has efficiently advanced early-stage research, producing preclinical data that meets the PCC nomination standards set by both companies [2] - The rapid achievement of the PCC nomination demonstrates the potential of AI-driven innovation in early drug development, particularly in addressing unmet clinical needs [2][3] - Haizheng Pharmaceutical expressed strong impressions regarding the efficiency and quality of the project, highlighting the integration of traditional pharmaceutical experience with cutting-edge AI technology as a key step in their digital transformation [3]

Core Viewpoint - The company InSilico Medicine officially listed on the Hong Kong Stock Exchange on December 30, marking a significant milestone in its growth and development within the biopharmaceutical sector [1]. Group 1: Company Overview - InSilico Medicine has established a team in Pudong since 2019, which has grown to nearly 200 members [1]. - The company plans to further deepen its business layout in Pudong and enhance team building focused on high-quality talent [1]. Group 2: Industry Context - Pudong has a vibrant biopharmaceutical ecosystem, featuring a dense concentration of related enterprises, research institutions, and professional talent [1]. - The ecosystem covers the entire chain from early exploration and clinical research to industrialization [1].

Core Insights - InSilico Medicine has become the first artificial intelligence biopharmaceutical company to list on the Hong Kong Stock Exchange under the main board listing rule 8.05, raising a total of HKD 2.277 billion, making it the highest fundraising biopharmaceutical IPO in Hong Kong for the year [1] - The IPO was co-sponsored by Morgan Stanley, CICC, and GF Securities, with a total issuance of 94.6905 million shares, of which 10% was allocated for public offering in Hong Kong, achieving an oversubscription rate of approximately 1,427.37 times, locking in subscription funds exceeding HKD 32.8349 billion [1] - The company plans to increase investment in its AI platform and innovative pipeline to accelerate the entry of more globally differentiated innovative projects into clinical trials [1] Company Collaborations - InSilico Medicine has established software licensing collaborations with 13 of the top 20 global pharmaceutical companies [2] - The company has also secured three pipeline licensing collaborations with Exelixis and Menarini, with a total collaboration potential of up to USD 2.1 billion, and has engaged in joint research collaborations with renowned pharmaceutical companies such as Fosun Pharma, Sanofi, and Eli Lilly [2] Key Asset - The core asset of InSilico Medicine is Rentosertib, a drug for treating idiopathic pulmonary fibrosis, which is the industry's most advanced first-in-class AI drug, having completed Phase IIa clinical trials domestically, marking a significant milestone in AI-driven drug development [1]

Group 1 - The core viewpoint of the article highlights that Ying Silicon Intelligence (03696.HK) experienced a significant stock price increase of over 11% on its second day of trading [1] - As of the time of reporting, the stock rose by 11.14%, reaching a price of 33.32 HKD [1] - The trading volume was reported at 83.89 million HKD, indicating strong market interest [1] Group 2 - The company's total market capitalization has surpassed 18 billion HKD, reflecting its positive reception in the market [1]

Core Viewpoint - The stock of Insilico Medicine (03696) surged over 11% on its second day of trading, reaching HKD 33.62, nearly a 40% increase from its IPO price of HKD 24.05 [1][3] Company Overview - Insilico Medicine was established in 2014 and is a leading company in AI-driven drug discovery and development in China [1][3] - As of December 10, 2025, the company has generated over 20 assets in clinical or IND application stages through its proprietary generative AI platform, Pharma.AI [1][3] Business Developments - Three of the assets have been licensed to international pharmaceutical companies, with a total contract value of up to USD 2.1 billion [1][3] - The company also has one asset in the II phase of independent development, which is considered to be at a leading stage in the industry [1][3] Market Performance - As of the latest update, the stock price increased by 11.74%, currently trading at HKD 33.50, with a trading volume of HKD 94.5447 million and a total market capitalization exceeding HKD 18 billion [1][3]